Investigating how ERK1/2 signaling affects immune response and lung damage from SARS-CoV-2.
Role of ERK1/2 signaling in SARS-CoV-2 -induced dysregulated immunity and lung pathology.
This study is looking at how a specific signaling pathway in our immune cells affects lung damage and inflammation in people with severe COVID-19, and it hopes to find ways to reduce harmful inflammation while boosting the body's ability to fight the virus, which could help patients with serious lung issues.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oklahoma State University Stillwater NIH-funded |
| Lab location | 1 site (Stillwater, United States) |
| Project ID | NIH-10812076 on NIH RePORTER |
What this research studies
This research focuses on understanding how the ERK1/2 signaling pathway influences the immune response and lung damage caused by the SARS-CoV-2 virus. By examining the role of myeloid cells and their signaling mechanisms, the study aims to identify how these cells contribute to excessive inflammation and impaired antiviral responses during COVID-19. The researchers will explore the potential of blocking ERK1/2 activity to reduce harmful inflammation while enhancing the body's ability to fight the virus. This could lead to new therapeutic strategies for patients suffering from severe lung complications due to COVID-19.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing severe respiratory symptoms or complications related to COVID-19.
Not a fit: Patients with mild COVID-19 symptoms or those not affected by respiratory issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for patients with severe COVID-19-related lung injuries.
How similar studies have performed: Other research has shown promising results in targeting similar pathways for treating viral-induced lung injuries, indicating potential for success in this approach.
Where this research is happening
Stillwater, United States
- Oklahoma State University Stillwater — Stillwater, United States (Active)
Researchers
- Principal investigator: Channappanavar, Rudragouda — Oklahoma State University Stillwater
- Study coordinator: Channappanavar, Rudragouda
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.